知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.011 seconds)

    MEASUREMENT OF FABP FOR DIAGNOSIS
    1.
    发明申请
    MEASUREMENT OF FABP FOR DIAGNOSIS 审中-公开

    公开(公告)号：US20190154672A1

    公开(公告)日：2019-05-23

    申请号：US16313316

    申请日：2017-06-30

    Applicant: Randox Laboratories Ltd. ,  Randox Teoranta

    Inventor： Ivan McConnell ,  Peter Fitzgerald ,  John Lamont ,  Ciaran Richardson

    IPC: G01N33/543 ,  G01N33/92 ,  C07K16/18

    Abstract: The present invention relates to a multiplexing system comprising a support substrate having immobilised thereto one or more of the following proteins, fragments thereof or a binding molecule, wherein the binding molecule binds specifically to one of the following proteins: E-FABP, B-FABP, IL-FABP, I-FABP, M-FABP, A-FABP, H-FABP, L-FABP or T-FABP. Another aspect is directed to a method for characterising the pattern of FABP antigens existing within a biological sample to reveal information useful in the diagnosis or disease or injury.

    METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
    2.
    发明申请
    METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE 审中-公开
    用于诊断阿尔茨海默病的方法和组合物

    公开(公告)号：US20160097780A1

    公开(公告)日：2016-04-07

    申请号：US14777718

    申请日：2014-03-04

    Applicant: RANDOX TEORANTA

    Inventor： Peter Fitzgerald ,  Ivan McConnell ,  John Lamont ,  Ciaran Richardson

    IPC: G01N33/68 ,  G06F19/24 ,  C12Q1/68

    CPC classification number: G01N33/6896 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2333/47 ,  G01N2333/4716 ,  G01N2333/76 ,  G01N2333/775 ,  G01N2333/81 ,  G01N2333/8121 ,  G01N2333/912 ,  G01N2800/2821 ,  G16B40/00

    Abstract: The present invention relates to methods for the diagnosis of subjects that have or are at risk of having Alzheimer's disease (AD). In particular the present invention identifies individuals who have or are at risk of having AD through measurement of the levels of Afamin in combination with at least one other biomarker such as Alpha-1-antichymotrypsin, Alpha-2-macroglobulin, ApoB100, Complement C5, Serine threonine protein kinase TBK1 or Complement C3 in a fluid sample taken from a subject. Furthermore, genotype (Apolipoprotein E or glutathione S-transferase Omega) may also be taken into consideration and used within classification algorithms to determine the probability of a subject having or being at risk of having AD.

    Abstract translation: 本发明涉及诊断患有阿尔茨海默病（AD）或有阿尔兹海默病（AD）风险的受试者的方法。 特别地，本发明通过与至少一种其它生物标志物如α-1-抗胰凝乳蛋白酶，α-2-巨球蛋白，ApoB100，补体C5的测量结合来测量具有或有风险患有AD的个体， 来自受试者的流体样品中的丝氨酸苏氨酸蛋白激酶TBK1或补体C3。 此外，还可以考虑基因型（载脂蛋白E或谷胱甘肽S-转移酶Omega）并在分类算法中使用，以确定受试者具有或具有AD风险的概率。

    Kidney disease biomarker
    4.
    发明授权
    Kidney disease biomarker 有权

    公开(公告)号：US10545157B2

    公开(公告)日：2020-01-28

    申请号：US15026577

    申请日：2014-10-06

    Applicant: Randox Teoranta

    Inventor： Ivan McConnell ,  Ciaran Richardson ,  John Lamont ,  Stephen Peter Fitzgerald

    IPC: G01N31/00 ,  G01N33/53 ,  G01N33/68

    Abstract: The disclosure provides methods and solid states devices for detecting and staging chronic kidney disease in a patient, where the levels of biomarkers in a sample obtained from a patient are elevated or reduced compared to the levels in a sample obtained from healthy subject. In addition, the disclosure provides the use of methods and solid state devices for measurement of specific biological markers for determining the efficacy of a treatment for chronic kidney disease and for determining a drug treatment protocol for a subject suffering from chronic kidney disease.

Patent Agency Ranking